Commonground
Senior Moderator
6 Mar 2026
Buenos Aires, March 6, 2026 (PAHO) — The Pan American Health Organization (PAHO) announced a technology transfer agreement for the cell-based production of seasonal influenza vaccines, coordinated with CSL Seqirus, using technology developed at its facility in the United States, and Sinergium, based in Argentina.
This initiative will modernize and strengthen local and regional vaccine production capacity by incorporating a more advanced platform than those traditionally used. The announcement was made during a visit to Argentina by PAHO Director Dr. Jarbas Barbosa.
“Regional vaccine production is an essential component of health security in the Americas. This agreement represents a concrete step to strengthen the region’s technological capacity, reduce external dependencies, and improve our preparedness for future epidemics and pandemics,” Barbosa said.
Unlike traditional egg-based methods, cell-based technology offers greater flexibility, scalability, and consistency in production processes, helping optimize manufacturing timelines, increase efficiency, and facilitate the development of seasonal influenza vaccines, including those with pandemic potential.
The agreement builds on the experience of PAHO’s Regional Revolving Funds in planning and consolidating vaccine demand across the region, as well as coordinating with countries, which helps ensure greater predictability and sustainability in access to these health technologies.
continued: https://www.paho.org/en/news/6-3-20...ment-argentina-strengthen-regional-production
Buenos Aires, March 6, 2026 (PAHO) — The Pan American Health Organization (PAHO) announced a technology transfer agreement for the cell-based production of seasonal influenza vaccines, coordinated with CSL Seqirus, using technology developed at its facility in the United States, and Sinergium, based in Argentina.
This initiative will modernize and strengthen local and regional vaccine production capacity by incorporating a more advanced platform than those traditionally used. The announcement was made during a visit to Argentina by PAHO Director Dr. Jarbas Barbosa.
“Regional vaccine production is an essential component of health security in the Americas. This agreement represents a concrete step to strengthen the region’s technological capacity, reduce external dependencies, and improve our preparedness for future epidemics and pandemics,” Barbosa said.
Unlike traditional egg-based methods, cell-based technology offers greater flexibility, scalability, and consistency in production processes, helping optimize manufacturing timelines, increase efficiency, and facilitate the development of seasonal influenza vaccines, including those with pandemic potential.
The agreement builds on the experience of PAHO’s Regional Revolving Funds in planning and consolidating vaccine demand across the region, as well as coordinating with countries, which helps ensure greater predictability and sustainability in access to these health technologies.
continued: https://www.paho.org/en/news/6-3-20...ment-argentina-strengthen-regional-production